



<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	10/667,216
		Filing Date	September 19, 2003
		First Named Inventor	Mousa
		Group Art Unit	1623
		Examiner Name	To Be Assigned
Total Number of Pages in This Submission	6	Attorney Docket Number	2747/1021

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> A copy of the Notice to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed, prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input checked="" type="checkbox"/> PTO-1449 Form and 32 references
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 14-1138 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Candice J. Clement Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (585) 263-1069 Fax: (585) 263-1600
Signature	<i>Candice J. Clement</i> Registration No. 39,946
Date	May 11, 2004

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____	
May 11, 2004 Date	<i>Ruth R. Smith</i> Signature Ruth R. Smith Typed or printed name



PATENT  
Docket No.: 2747/1021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Shaker A. Mousa	)	Examiner:
			)	To Be Assigned
Serial No.	:	10/667,216	)	
			)	Art Unit:
Cnfrm. No.	:	7027	)	1623
			)	
Filed	:	September 19, 2003	)	
			)	
For	:	OXIDIZED HEPARIN FRACTIONS AND	)	
		THEIR USE IN INHIBITING ANGIOGENESIS	)	

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98

**Mail Stop:**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.97(b)(3), no fee is required. Should it be determined that a fee is required, however, the Commissioner is hereby authorized to charge any fee to Deposit Account No. 14-1138.

Respectfully submitted,

Date: May 11, 2004

Candice J. Clement  
Candice J. Clement  
Registration No. 39,946

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1069  
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
May 11, 2004	Ruth R. Smith
Date	Ruth R. Smith



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/667,216
				Filing Date	September 19, 2003
				First Named Inventor	Shaker A. Mousa
				Art Unit	1623
				Examiner Name	To Be Assigned
Sheet	1	of	4	Attorney Docket Number	2747/1021

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,092,885	03/03/1992	Yamada et al.	
	2	US-5,112,946	05/12/1992	Maione	
	3	US-5,192,744	03/09/1993	Bouck et al.	
	4	US-5,202,352	04/13/1993	Okada et al.	
	5	US-5,639,725	06/17/1997	O'Reilly et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	Braswell, E., "Heparin: Molecular Weight and Degradation Studies," <i>Biochim. Biophys. Acta</i> 158:103-116 (1968)	
	7	Kosakai et al., "Isolation and Characterization of Sulfated Disaccharides from the Deamination Products of Porcine Heparin ( $\alpha$ -Heparin) and Whale Heparin ( $\omega$ -Heparin), and a Comparison of the Deamination Products," <i>J. Biochem.</i> 83:1567-1575 (1978)	
	8	Fransson, et al., "Relationship Between Anticoagulant Activity of Heparin and Susceptibility to Periodate Oxidation," <i>FEBS Letters</i> 97:119-123 (1979)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>			
				Application Number		10/667,216	
				Filing Date		September 19, 2003	
				First Named Inventor		Shaker A. Mousa	
				Group Art Unit		1623	
				Examiner Name		To Be Assigned	
Sheet	2	of	4	Attorney Docket Number		2747/1021	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	9	Fujita et al., "Improvement of Treadmill Capacity and Collateral Circulation as a Result of Exercise with Heparin Pretreatment in Patients with Effort Angina," <i>Circulation</i> 77:1022-1029 (1988)	
	10	Rastinejad et al., "Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene," <i>Cell</i> 56:345-355 (1989)	
	11	Moses et al., "Identification of an Inhibitor of Neovascularization from Cartilage," <i>Science</i> 248:1408-1410 (1990)	
	12	Blood et al., "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta</i> 1032:89-118 (1990)	
	13	Oikawa et al., "Angiogenic Factor of a Rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of Two Distinct Angiogenic Factors into Serum-Free Conditioned Medium by RMT-1 Cells," <i>Cancer Letters</i> 59:57-66 (1991)	
	14	Buckley et al., "Enoxaparin: A Review of its Pharmacology and Clinical Applications in the Prevention and Treatment of Thromboembolic Disorders," <i>Drugs</i> 44:465-497 (1992)	
	15	Clapp et al., "The 16-Kilodalton N-Terminal Fragment of Human Prolactin Is a Potent Inhibitor of Angiogenesis," <i>Endocrinology</i> 133:1292-1299 (1993)	
	16	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases," <i>Cell</i> 79:315-328 (1994)	
	17	Chen et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors," <i>Cancer Research</i> 55:4230-4233 (1995)	
	18	Schnaper et al., "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>Journal of Cellular Physiology</i> 165:107-118 (1995)	
	19	Larnkjaer et al., "Isolation and Characterization of Hexasaccharides Derived from Heparin. Analysis by HPLC and Elucidation of Structure by <sup>1</sup> H NMR," <i>Carbohydrate Research</i> 266:37-52 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number		10/667,216
				Filing Date		September 19, 2003
				First Named Inventor		Shaker A. Mousa
				Group Art Unit		1623
				Examiner Name		To Be Assigned
Sheet	3	of	4	Attorney Docket Number		2747/1021

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	20	Strieter et al., "Interferon $\gamma$ -Inducible Protein 10 (IP-10), a Member of the C-X-C Chemokine Family, is an Inhibitor of Angiogenesis," <i>Biochemical and Biophysical Research Communications</i> 210:51-57 (1995)	
	21	Angiolillo et al., "Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo," <i>J. Experimental Medicine</i> 182:155-162 (1995)	
	22	Parangi et al., "Antiangiogenic Therapy of Transgenic Mice Impairs <i>de novo</i> Tumor Growth," <i>Proc. Natl. Acad. Sci. USA</i> 93:2002-2007 (1996)	
	23	Risau, "Mechanisms of Angiogenesis," <i>Nature</i> 386:671-674 (1997)	
	24	Mulloy et al., "Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography," <i>Thrombosis and Haemostasis</i> 4:668-674 (1997)	
	25	Dickinson et al., "Enoxaparin Increases the Incidence of Postoperative Intracranial Hemorrhage when Initiated Preoperatively for Deep Venous Thrombosis Prophylaxis in Patients with Brain Tumors," <i>Neurosurgery</i> 43:1074-1081 (1998)	
	26	Linhardt et al., "Production and Chemical Processing of Low Molecular Weight Heparins," <i>Seminars in Thrombosis and Haemostasis</i> 25:5-16 (1999)	
	27	Kosir et al., "Degradation of Basement Membrane by Prostate Tumor Heparanase," <i>Journal of Surgical Research</i> 81:42-47 (1999)	
	28	Kakkar et al., "Antithrombotic Therapy in Cancer," <i>BMJ</i> 318:1571-1572 (1999)	
	29	Hettiarachchi et al., "Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread," <i>Thrombosis and Haemostasis</i> 82:947-952 (1999)	
	30	Mousa et al., "Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography," <i>Arterioscler. Thromb. Vasc. Biol.</i> 20:1162-1167 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>			
				Application Number		10/667,216	
				Filing Date		September 19, 2003	
				First Named Inventor		Shaker A. Mousa	
				Group Art Unit		1623	
				Examiner Name		To Be Assigned	
Sheet	4	of	4	Attorney Docket Number		2747/1021	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	31	Arkel, "Thrombosis and Cancer," <i>Seminars in Oncology</i> 27:362-374 (2000)	
	32	Zacharski et al., "Low-Molecular-Weight Heparin and Cancer," <i>Seminars in Thrombosis and Hemostasis</i> 26:69-77 (2000)	
	33	Eriksson et al., "Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery," <i>N. Engl. J. Med.</i> 345:1298-1304 (2001)	
	34	Smorenburg et al., "The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies," <i>Pharmacological Reviews</i> 53:93-105 (2001)	
	35	Mousa et al., "Comparison of the Effect of Different Platelet GPIIb/IIIa Antagonists on the Dynamics of Platelet/Fibrin-Mediated Clot Strength Induced Using Thromboelastography," <i>Thrombosis Research</i> 104:49-56 (2001)	
	36	Morita et al., "High Affinity Binding of Heparin by Necrotic Tumour Cells Neutralises Anticoagulant Activity," <i>Thromb. Haemost.</i> 86:616-622 (2001)	
	37	Prandoni, "Heparins and Venous Thromboembolism: Current Practice and Future Directions," <i>Thromb. Haemost.</i> 86:488-498 (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.